Vol 52 No 07

"I think the micronized formulation is something to think about," says Gautam Jayram, MD.

Urology Times’ exclusive survey reveals urologists/advanced practice providers’ thoughts on reusable vs disposable cystoscopes.

"As the markets continue to push record highs, staying disciplined in your investment strategy, removing emotion from your decision-making, and sticking to an appropriate investment allocation will be vital to navigating market swings," writes Jeff Witz, CFP.

"Ultimately, it is best to report CPT 50548 (only) for the performance of a typical laparoscopic nephroureterectomy," write Jonathan Rubenstein, MD, and Mark Painter.

“The PRO data presented here complements the published clinical efficacy and safety data, add the patient's voice, and support the use of EV/pembro for patients with locally advanced/metastatic urothelial cancer," says Shilpa Gupta, MD.

A post-hoc analysis of the phase 3 ARAMIS trial provided additional efficacy evidence for darolutamide in nmCRPC, including benefits related to prostate cancer–specific survival and reaching a PSA level <0.2 ng/mL.

Patients with advanced renal cell carcinoma treated with TKIs in the second or third line following lenvatinib treatment showed modest activity, highlighting the need for improved treatment options.

In the EMBARK trial in patients with nonmetastatic hormone-sensitive prostate cancer, patients with good PSA responses at 37 weeks had their treatment suspended until their PSA started to rise again.

The IND acceptance will initiate the launch of a phase 1 trial to evaluate the safety, tolerability, and preliminary anti-tumor activity of 225Ac-FL-020 in patients with mCRPC.

"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this technology," says Brittany Hunt.

Regarding patient-reported outcomes, those who underwent URS showed higher urinary symptoms, greater pain intensity, and greater pain interference at 1 week following surgery compared with those who underwent SWL.

"So, there's a lot of evidence to point to the androgen receptor being an important player in at least developing this disease," says Edward M. Messing, MD.

“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.

Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.

"At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable as possible," says Ruchika Talwar, MD.

"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.

The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of grade group 3 or higher.